Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion‐transmitted HCV infection

Legler, Tobias J.; Riggert, Joachim; Simson, G.; Wolf, Claudia; Humpe, Andreas; Munzel, Ullrich; Uy, Angela; Köhler, Michael; Heermann, Klaus-Hinrich

doi:10.1046/j.1537-2995.2000.40101192.x

Cited by 35 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain authors have advocated screening of HCV-RNA in addition to anti-HCV. 10,19 The major drawback of this method is that the cost may be prohibitively high for routine use in a developing country such as Malaysia. Others have suggested the use of blood from repeat donors, rather than from new donors.…”

Section: Discussionmentioning

confidence: 99%

Risks of seroconversion of hepatitis B, hepatitis C and human immunodeficiency viruses in children with multitransfused thalassaemia major

Lee¹,

Teh²,

Chan³

2005

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Risks of seroconversion of hepatitis B, hepatitis C and human immunodeficiency viruses in children with multitransfused thalassaemia major

Lee¹,

Teh²,

Chan³

2005

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

“…Transmission of HCV has been efficiently prevented by improved blood screening and by implementation of virucidal treatments of plasma pools that eliminate the residual risk of HCV in anti-HCV-negative blood donations. As the latter risk (1 in 100 000) occurs in the interval between infection and the development of detectable anti-HCV (< 12 weeks) [36], virus safety of plasma pools can be further improved by direct screening of pooled samples by PCR, a procedure that decreases the window period after infection to about 3 weeks [37]. It is now well established that many patients infected with HCV will have a slowly progressive liver disease, but in a minority hepatitis will progress to ESLD or HCC.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C in haemophilia: lights and shadows

et al. 2004

View full text Add to dashboard Cite

Hepatitis C is a major cause of morbidity and mortality in haemophiliacs who received clotting factor concentrates before the availability of virus-inactivated factors in the mid-1980s. Early studies gave conflicting indications as to the severity of hepatitis C (originally termed non-A non-B hepatitis), as mild, slowly progressive hepatitis was documented in several infants and young adults with haemophilia who were examined with repeat liver biopsies, whereas more progressive hepatitis and cirrhosis was documented in others. One major point of dispute was whether these discrepancies could in part be accounted for by epidemiological differences among studies, as hepatitis C acquired early in life may initially run a benign course and later worsen owing to spontaneous recrudescence of hepatitis or interference with such comorbidity factors as alcohol abuse or infection with the human immunodeficiency virus (HIV). In the mid 1990s, the latter infection overshadowed hepatitis C as a cause of death in this patient population. Because hepatocellular carcinoma is emerging as an important complication in haemophiliacs with long-standing hepatitis C virus (HCV) infection who survived HIV infection, and because of recent advances in treating HIV, morbidity and mortality associated with chronic hepatitis C have regained emphasis amongst haemophiliacs. The development of newer interferon-based therapies provides an opportunity for modifying the natural history of HCV infection in a substantial number of haemophilic patients.

show abstract

“…Serum samples were processed using the MagNA Pure LC instrument and run on the COBAS TaqMan Both qualitative and quantitative hepatitis C virus (HCV) RNA tests are used in diagnosis and management of patients with hepatitis C, because no single commercially available test combines high analytical sensitivity with a broad dynamic range. Qualitative nucleic acid amplification tests for detection of HCV RNA in serum are used to confirm the diagnosis of hepatitis C, distinguish active from resolved infection, assess virological response to therapy, and screen blood donors (3,18,23). Quantitative tests are used in evaluation of patients being considered for therapy and to assess early response to therapy.…”

mentioning

confidence: 99%

“…Qualitative nucleic acid amplification tests for detection of HCV RNA in serum are used to confirm the diagnosis of hepatitis C, distinguish active from resolved infection, assess virological response to therapy, and screen blood donors (3,18,23). Quantitative tests are used in evaluation of patients being considered for therapy and to assess early response to therapy.…”

mentioning

confidence: 99%

Performance Characteristics of a Quantitative TaqMan Hepatitis C Virus RNA Analyte-Specific Reagent

et al. 2004

View full text Add to dashboard Cite

We determined the dynamic range, reproducibility, accuracy, genotype bias, and sensitivity of the TaqMan hepatitis C virus (HCV) analyte-specific reagent (ASR). Serum samples were processed using the MagNA Pure LC instrument and run on the COBAS TaqMan Both qualitative and quantitative hepatitis C virus (HCV) RNA tests are used in diagnosis and management of patients with hepatitis C, because no single commercially available test combines high analytical sensitivity with a broad dynamic range. Qualitative nucleic acid amplification tests for detection of HCV RNA in serum are used to confirm the diagnosis of hepatitis C, distinguish active from resolved infection, assess virological response to therapy, and screen blood donors (3,18,23). Quantitative tests are used in evaluation of patients being considered for therapy and to assess early response to therapy. A pretreatment viral load of less than 800,000 IU/ml is one of several predictors of a sustained virological response (20,24). Viral load testing has also been used in early assessment of treatment response. Patients who fail to achieve at least a 2-log 10 decline in viral load after 12 weeks of treatment have little chance of a sustained response and can be spared the cost and toxicity of a complete treatment course (9, 17). However, viral load does not predict the progression of hepatitis C and is not associated with the severity of liver disease.A variety of tests for detection and quantitation of HCV RNA based on different nucleic acid amplification technologies are commercially available. The qualitative AMPLICOR HCV and quantitative AMPLICOR HCV MONITOR version 2.0 tests (Roche Diagnostics Corporation, Indianapolis, Ind.) are based on conventional reverse transcription-PCR in a heterogeneous format (17). The VERSANT HCV RNA qualitative and VERSANT HCV RNA 3.0 quantitative assays (Bayer Healthcare, Tarrytown, N.Y.) are based on transcription-mediated amplification and branched DNA signal amplification, respectively (10, 15).These tests also differ in their lower limits of detection and dynamic ranges. The qualitative AMPLICOR and VERSANT tests have lower limits of detection of 50 and 5 IU/ml, respectively. Although the lower limits of detection for the quantitative AMPLICOR and VERSANT tests are both approximately 600 IU/ml, the dynamic ranges differ by approximately 1 log 10 and are 3.1 and 4.1 log 10 , respectively. Because of the differences in sensitivity between the qualitative and quantitative assays, many clinical laboratories use a quantitative test to determine viral load and a sensitive qualitative test for diagnosis and test-of-cure. A single test with sensitivity similar to the qualitative tests that accurately quantitates high viral loads would be beneficial for clinical laboratories.A number of homogeneous TaqMan reverse transcription-PCR assays for detection and quantitation of HCV RNA have been described (12,13,19,21,29). These tests are very sensitive, have broad dynamic ranges, and provide precise quantitation of viral load. These tes...

show abstract

Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion‐transmitted HCV infection

Cited by 35 publications

References 22 publications

Risks of seroconversion of hepatitis B, hepatitis C and human immunodeficiency viruses in children with multitransfused thalassaemia major

Risks of seroconversion of hepatitis B, hepatitis C and human immunodeficiency viruses in children with multitransfused thalassaemia major

Hepatitis C in haemophilia: lights and shadows

Performance Characteristics of a Quantitative TaqMan Hepatitis C Virus RNA Analyte-Specific Reagent

Contact Info

Product

Resources

About